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Peroxisome proliferator-activated receptors (PPARs) are key regulators in various age-associated pathophysiological processes re-
lated to energy metabolism and oxidative stress. A progressive rise of oxidative stress and related inﬂammatory reaction appears
the hallmarks of the aging process and many age-related diseases. PPARs are important redox-sensitive transcription factors and
their dyregulated activations seem to be major culprits for these pathological processes. Drugs targeting PPARs activity are already
in widespread clinical use; however, based on these concepts, this review highlights the understanding of the role of PPARs in
aging and indicates the necessary particular attention for the potential therapeutic uses of current PPAR agonists in age-associated
diseases.
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1. INTRODUCTION
Why and how does aging occur? This is the most interest-
ing scientiﬁc question. A large number of theories of ag-
ing have been proposed. However, any appropriate theory
must explain four main characteristics of aging: it is pro-
gressive, endogenous, irreversible, and deleterious for the in-
dividual [1]. Ageing is associated with immunosenescence;
decreased hormonal secretion, metabolism, lean body, and
bone mass; and increased fat accretion. As a consequence,
inﬂammatorydiseases,dyslipidemia,atherosclerosis,obesity,
and type 2 diabetes incidence increases with age [2]. Most
of those prominent features of aging are related to perox-
isome proliferator-activated receptors (PPARs) activity. Ac-
tually, the elderly population, particularly in the industrial-
ized world, is exposed over its life span to an ever increasing
number of agonists of PPARs in the form of various thera-
peutic agents and environmental pollutants through respira-
t i o n ,i nf o o d ,a n dw a t e r[ 3]. Hence in this review, two im-
portant PPARs-oriented characteristic mechanisms in aging,
increasedoxidativestressanddecreasedfuelmetabolism,will
beintroducedbrieﬂyandthentheroleofPPARsinthesepro-
cesses will be discussed.
2. OXIDATIVE STRESS IN AGING
One of the prevalent theories in the current literature re-
volves around free radicals as causal agents in the process of
aging. A range of 1–3% of inspired oxygen was metabolized
to superoxide and hydrogen peroxide. Free radical reactions
are ubiquitous in living systems. Life is apparently evolved
spontaneously from basic chemicals, formed by free radical
reactions largely initiated by ionizing radiation from the sun,
so that life span evolved in parallel with the ability of organ-
isms to deal with damage from free radicals [4].
In 1956, Denham Harman was the ﬁrst to propose the
visionary “free radical theory” of aging [5]. This concept re-
ceived strong support in the 1970s from voluminous, partic-
ularly from the mitochondrial studies. It was subsequently
discovered that reactive oxygen species (ROS) contribute
to the accumulation of oxidative damage to cellular con-
stituents. There is indisputable evidence of the formation of
a range of macromolecular oxidation products encompass-
ing lipids, proteins, and nucleic acids, presumably arising
from ROS activity. However, counterbalancing oxygen rad-
ical damage, there exists a wide range of enzyme repair and
small molecule scavenging [6].
One of the several theories concerning ROS component
that has been extensively studied is the mitochondrial theory
of aging, which hypothesizes that mitochondria are the crit-
ical component in control of aging. It is proposed that elec-
trons leaking from the electron transport chain (ETC) pro-
duceROSandthesemoleculescanthendamageETCcompo-
nents and mitochondrial DNA, leading to further increases
in intracellular ROS levels and a decline in mitochondrial2 PPAR Research
function. In support of a mitochondrial theory of aging, evi-
dence suggests that mitochondrial DNA damage is increased
with aging [7].
Mitochondria were brought to attention in aging biol-
ogy due to (1) the central role of mitochondria in producing
chemical energy (ATP) to meet cellular requirements, and
(2) the declines of basal metabolic rate and of physical per-
formance in energy-requiring tasks, which are characteris-
tic of the aging process [8]. Hence, mitochondria are con-
sidered the pacemakers of tissue aging due to the continu-
ous production of oxygen, nitrogen free radicals, and related
reactive species; and due to the selective oxidative damage
that leads to mitochondrial dysfunction. It is now clear that
mammalian life span is negatively related to the mitochon-
drial production of oxidizing free radicals and the dysfunc-
tional mitochondria that determine mitochondrial and cel-
l u l a rt u r n o v e r[ 8].
The age-related oxidative damage is, in a ﬁrst approxi-
mation, due to an increased rate of generation of oxidant.
Caloric restriction (CR) is the most eﬀective intervention
known to delay aging and increase life span. There is now ev-
idence indicating that CR acts by decreasing oxidative stress
and damage. Mitochondrial function and CR are apparently
related to decreased superoxide production [9]. CR, a potent
experimental paradigm forthe retardation of aging, has been
shown to exhibit broad and eﬀective antioxidant properties,
and anti-inﬂammatory eﬀect [10]. The beneﬁcial diverse an-
tiaging eﬀects of CR are associated with altered metabolism,
particularly, reduced metabolic rate and oxidative stress; de-
creased fat mass, body temperature, and fasting glucose; im-
proved insulin sensitivity; and altered neuroendocrine and
sympathetic system [11]. Moreover, the study results indi-
cated that CR decreased the expression of PPARγ,P P A R α,
and PPARβ/δ, which would lead to downregulation of fat
metabolism [12].
3. ENERGY METABOLISM IN AGING
Fatty acids are a major substrate for oxidative energy meta-
bolism in muscle, and indeed 60–90% of total oxygen con-
sumption may be used to oxidize fatty acids. Fatty acids are
oxidized in preference to carbohydrates. Oxidation of fatty
acids or ketone bodies inhibits the utilization of both extra-
cellular glucose and tissue glycogen [13]. Long-chain fatty
acids(LCFAs)arethemajorcomponentofdietarylipids,and
carnitine palmitoyl transferase-1 (CPT-1) is a rate-limiting
enzyme for β-oxidation of LCFA in mitochondria [14]. Re-
duced fatty acid oxidation and/or CPT-1 cause accumula-
tion of triglyceride in tissue and are associated with many
metabolic disorders [15].
Aging causes many changes in the energy metabolism
of the muscle, particularly heart muscle. The aging my-
ocardium shifts its fuel preference away from fatty acid ox-
idation (FAO) toward carbohydrate oxidation, which is a re-
version to the neonatal state [16]. It was shown that mito-
chondria isolated from the hearts of senescent rats show a
20% lower rate of LCFA oxidation than mitochondria from
young adult animals do. Conceivably, the overall rate of en-
ergy transduction by the mitochondria might be decreased,
placing a limitation on the intensity of performance of me-
chanical work [17]. Interestingly, there is no evidence to sug-
gest that the CPT-1 is the site of age-linked lesion suggesting
CPT-1 activity is not changed with age. In stead, diminished
mitochondrial content seems responsible for the reduction
in FAO [18]. This change in fuel preference is typically par-
alleled by a reorganization of mitochondrial metabolism, in-
cluding a shift in the gene expression and relative activities
of FAO enzymes. This switch in fuel preference is thought to
be maladaptive and contribute to the contractile dysfunction
[19].
Aging is associated with increased body fat especially
in the visceral area and peripheral tissues such as liver
and skeletal muscle, and might be responsible for the age-
associated increased risk for type 2 diabetes, hypertension,
and atherosclerosis [20]. Recent studies have demonstrated
a strong relationship between aging-associated reductions
in mitochondrial function, dysregulated intracellular lipid
metabolism, and insulin resistance. Petersen et al. showed
that the older subjects were markedly resistant to insulin,
as determined by the reduced insulin stimulation of mus-
cle glucose metabolism [21]. Insulin resistance in the skele-
tal muscle of elderly is a linked defect to mitochondrial ox-
idativephosphorylation.However,furtherresearchesdidnot
show changes in mitochondrial energy coupling [22]. This
suggested an age-related reduction of mitochondrial num-
ber and/or function as the most likely culprit to explain the
deﬁcient energy metabolism of aging.
4. PPARs—AN OUTLINE
PPARα, δ,a n dγ are nuclear transcription factors to the nu-
clear hormone receptor superfamily that controls key genes
involved in energy homeostasis [23]. Consequently, PPARs
play major roles in a broad spectrum of biological processes,
including cell proliferation, diﬀerentiation, glucose home-
ostasis, eicosanoid signaling, insulin sensitivity, glucose and
lipid metabolism, bone formation, and tissue remodeling
[24]. A thorough examination of the biology of the PPARs
is beyond the scope of this review; the reader is referred to
more specialized reviews on this topic in [25–27].
PPARs require retinoid X receptors to form heterodim-
ers, which allow binding to their speciﬁc PPAR-response el-
ements (PPREs). Much is known about the activation of
PPARs via PPREs and in most cases this leads to transcrip-
tionalactivationofthetargetgenes([25]fordetailedreview),
but far less information exists for the mode of PPAR mod-
ulation during aging. However, an age-related reduction of
PPARα in both mRNA and nuclear protein levels was shown
[28].
What is the signiﬁcance of multiple PPAR isoforms with
distinct expression patterns? One possibility is that the three
isoforms have diﬀerent ligand speciﬁcities. Thus, the ratio of
these receptors and their ligands provide a means of deter-
mining tissue-speciﬁc expression of target genes. In addition
to their diﬀerential responsiveness to peroxisome prolifera-
tors, the three PPAR isoforms also display distinct yet over-
lapping expression patterns. The ratio of the PPAR isoforms,Adnan Erol 3
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Figure 1: The main pathophysiological processes and their interac-
tionsleadingtoagingaredepicted.Themostlikelyinhibitingpoints
ofPPARsareindicatedaspossibletargetsforpharmacologicaltreat-
ment. Controversial issue of PPARs on atherosclerosis is marked by
broken arrow.
however, is likely to play a critical role in establishing the de-
gree of responsiveness of tissues to speciﬁc activators [29].
There is evidence that PPARα plays multiple roles in the
aging process. PPARα may inﬂuence aging through regula-
tion of damage and repair processes after exposure to en-
dogenous or environmental stressors. Corton et al. showed
that PPARα reduces the severity and frequency of a subset of
age-dependent lesions in the mouse. These ﬁndings were in
the liver, the kidney, and the heart, in which PPARα is nor-
mally expressed, mediates regulation of lipid metabolizing
genes, and regulates genes involved in maintaining the in-
tegrity of these tissues [30]. However, in the aged liver, a de-
crease in hepatic antioxidant activity, coupled with a PPARα
agonist-induced increase in liver oxidative stress and anti-
apoptotic eﬀect of PPARα agonists may expose these livers
to the point of tumor formation [31].
Genetically long-lived mice are good animal models to
estimate the importance of PPARs in longevity. Growth hor-
mone receptor/binding protein knockout (GHR-KO) mice
are characterized by markedly extended lifespan in compar-
ison to normal controls. Interestingly, in contrast to GH-
deﬁcient and GH-resistant mutants, GH antagonist trans-
genicmiceshowedstriking diﬀerencesforseveralparameters
including longevity. These mice are GH resistant or insen-
sitive, have greatly reduced plasma IGF-I and insulin levels,
a n dh a v el o wg l u c o s el e v e l[ 32]. There are numerous indi-
cations that insulin, insulin release, and insulin actions play
a major role in the control of mammalian aging. A recent
report of increased life span in transgenic Klotho mice that
are insulin-resistant raises the interesting possibility that ag-
ing can be delayed by reduced strength of the insulin sig-
nal, regardless of its underlying causes [33]. It has been hy-
pothesized that insulin resistance is a physiological protec-
tionmechanismagainstagingandage-relateddisorders[34].
GHR-KO mice have signiﬁcantly elevated PPARγ,
mRNA, and protein level in the liver. However, PPARγ pro-
tein level in skeletal muscle was decreased in comparison to
normal controls. The increased level of PPARα in the liver of
these mice suggests an increased FAO, which could be ben-
eﬁcial for insulin sensitivity. Similarly, PPARα level in the
muscle was decreased in GHR-KO animals. PPARβ/δ pro-
teins were downregulated in the liver and skeletal muscle of
KO mice ([35] and references therein).
As noted above, much of the accumulated evidence
strongly implicates oxidative stress as a major factor con-
tributing to the aging process and age-related diseases. Re-
cent molecular studies show that the induction of oxidative
stress is associated with the downregulation of PPARs [28].
More interestingly, the possible inverse association between
age-related changes in PPARs levels and oxidative stress was
further supported by the antioxidative action of CR. The re-
sults showed the antioxidative eﬀects of CR blunt age in-
duced decreases in PPARα,P P A R γ, and mRNA levels; and in
protein expression. Data further revealed that CR improved
the age-induced decrease in PPAR DNA binding activity to
PPRE. Also, CR induced prevention of the age-related de-
cline in PPARs may partly reason in the suppression of the
age-induced increased inﬂammation [28].
5. PPARs AND INFLAMMATION IN AGING
The freeradicaltheory ofagingserves toexplain not onlyba-
sic mechanisms of aging but also the pathogenesis of a range
of disease processes that consistently accompany aging, in-
cluding atherosclerosis, other cardiovascular disorders, de-
mentia, diabetes, arthritis, and osteoporosis [36]. In evaluat-
ing the free radical theory and its possible link to numerous
age-related maladies, investigators have focused attention on
thepossibilitythatanincreaseinROS,alongwithaconcomi-
tant disruption in redox balance, leads to a state of chronic
inﬂammation (see Figure 1)[ 37].
Inﬂammation is a primary defense against threats to
homeostasis. With aging, inﬂammatory responses may be
overactive or even cause damage, resulting in adverse patho-
logical conditions [38]. Oxygen and nitrogen-derived re-
active species coupled with a deﬁcient antioxidant de-
fense capacity cause the redox imbalance. This oxidative
stress-induced redox imbalance, in turn, activates many of
redox-sensitive transcription factors, which generates vari-
ous proinﬂammatory molecules [39]. Evidence also impli-
cates the involvement of PPARs at the transcriptional level in
the expression of proinﬂammatory mediators such as, nu-
clear factor-κB( N F - κB), signal transducers and activators
of transcription (STAT)-1, and activating protein-1 (AP-1)
[40]. In addition, several studies have demonstrated that
PPARα and PPARγ inhibit the expression of inﬂammatory
genes, such as cytokines, metalloproteases, and acute phase
proteins [41].
Premature and enhanced age-dependent rise of oxida-
tive stress and NF-κB activation in the PPARα knockout
mice have been reported [42]. Ligand-activated PPARα can
suppress inﬂammatory reactions by inhibiting NF-κBf u n c -
tion. EnhancedIL-6production by activatedNF-κBh a sbee n
implicated in many pathophysiological dysfunctions of ag-
ing ranging from Alzheimer’s disease to atherosclerosis [43].
However, intriguingly, high doses of the PPARα subtype-
speciﬁc ligand cause a marked activation of NF-κB, whereas
low or therapeutic doses of the hypolipidemic agents cause
decreased NF-κB activation, IL-6 production, and lipid per-
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All major vascular and inﬂammatory cells express
PPARγ, including vascular smooth muscle cells, endothe-
lial cells, and macrophages [44]. PPARγ is expressed in
monocytes and upregulated during their diﬀerentiation into
macrophages [45]. Furthermore, PPARγ ligands inhibit the
production of proinﬂammatory cytokines, TNFα,a n dI L - 1
[46]. These studies along with the observation of decreased
carotid intima-media thickness in diabetic patients treated
withthePPARγ agonisttroglitazone[47]suggestthatPPARγ
activationmightpreventatherogenesis.Thesevasculoprotec-
tive eﬀects of PPARγ agonists in humans may be attributed
to their eﬀects on inﬂammation [48]. On the other hand,
PPARγ activation induces expression of the scavenger recep-
tor CD36, thereby promoting oxidized low density lipopro-
tein uptake and foam cell formation, predicting that PPARγ
is predominantly proatherogenic [43]. In addition, very re-
cent meta-analysis, paradoxically, showed a signiﬁcant in-
crease in the risk of myocardial infarction and an increase in
cardiovascular death of borderline signiﬁcance with rosigli-
tazone, a member of PPARγ agonists that is widely used as
antidiabetic agent [49]. These confusing results, obviously,
will create a lot of trouble for the clinical use of the agent,
and further studies are required to deﬁne how much of these
eﬀectsaretheresultofPPARγ’sbeneﬁcialsystemicmetabolic
eﬀects versus its vascular and immune eﬀects [50].
6. PPARs AND FUEL METABOLISM
Aged mammals, including humans, show a decreased capac-
ity for FAO [51]. This may be an underlying cause of age-
related decrease in energy metabolism, and increase in dys-
lipidemia. PPARα is one of the primary metabolic nuclear
receptors that act as sensors of fatty acid and other metabo-
lites to enable the organism to adapt quickly to environmen-
tal changes by inducing or inhibiting appropriate metabolic
genes and pathways [52].
PPARαisexpressedinmetabolicallyactivetissuesinclud-
ing the liver, heart, kidney, and skeletal muscle [53]. Fatty
acids are the primary natural ligands of PPARα, which ac-
tivates genes for fatty acid uptake and oxidative catabolism
[54]. Fibrates are one of the synthetic ligands for PPARα,an d
glucocorticoids induce PPARα in response to stress [55] in-
dicating that situations of stress can enhance the impact of
nutritional factors on metabolic processes.
Data indicate a more general role for the major impor-
tance of PPARα in the regulation of a mitochondrial ox-
idative enzyme gene because the mitochondrial FAO path-
w a yi st h ep r i m a r ys o u r c eo fc e l l u l a re n e r g yi nm a n yt i s -
sues [56]. However, PPARα and β/δ are known to have over-
lapping roles in activating FAO as demonstrated through
the use of PPARα null mice. There were no obvious diﬀer-
ences in FAO capacity, and the response to exercise was com-
parable between skeletal muscle of PPARα null and wild-
type mice [57]. In addition, the PPARα agonist fenoﬁbrate
markedly increased fatty acid oxidation by the liver, but not
by the skeletal muscle [58]. Furthermore, muscle from trans-
genic mice with a constitutively activated form of PPARβ/δ
in skeletal muscle was composed of larger proportion of high
oxidative capacity type I muscle ﬁbres [59]. This led the in-
vestigators to conclude that PPARβ/δ is abundantly present
in skeletal muscle, and skeletal muscle PPARβ/δ largely com-
pensatesforthelackofPPARαinthenullmice.However,itis
unclear whether a crosstalk exists between these two nuclear
receptors and whether they regulate cardiac FAO homeosta-
sis independently. More importantly, PPARβ/δ was relatively
unaﬀected by aging [57]. The actions of PPARβ/δ in skeletal
muscle, that is, oxidative myoﬁber remodeling and increase
of fatty acid burning capacity [60], may give hope to the spe-
ciﬁc agonists of this nuclear receptor for therapeutic useful-
ness in the age-related metabolic diseases.
In both cardiac and skeletal muscle all three isoforms in
the following ranking order: PPARβ/δ>PPARα>PPARγ
could be detected. PPARγ expression is conﬁned to a lim-
ited number of tissues, primarily adipose tissue, and vascular
cells [61]. The expression of PPARγ in muscle cells has been
controversial issue, if present at all, the amount of PPARγ
in these cells is probably low [62]. The enhanced expres-
sion of PPARγ within skeletal muscle cell under certain con-
ditions may transdiﬀerentiate into adipocyte-like cells [63].
Concerning the importance of age-associatedsarcopenia,the
use of medicine forcing PPARγ activation needs much more
attention in aged people.
7. PPARs AND METABOLIC SYNDROME IN
AGED PATIENTS
Aging has been associated with a reduced capacity for ox-
idative phosphorylation in muscle, most likely due to a de-
cline in mitochondrial content and/or function [64]. Given
the strong evidence linking mitochondrial dysfunction with
aging, insulin resistance, and type 2 diabetes [22], it is im-
portant to determine the signiﬁcance of the clinical inter-
ventions with PPAR agonists. Furthermore, the clustering
of these metabolic risk factors termed metabolic syndrome,
which consequently increases the likelihood of atheroscle-
rotic cardiovascular diseases, tends to increase with aging
(see Figure 1)[ 65].
It is well established that insulin sensitivity normally de-
clines with age in humans [66]. Thiazolidinedione (TZD)
compounds are a new class of insulin-sensitizing drugs [67],
which improve insulin sensitivity, glucose tolerance, and the
lipidemic proﬁle in type 2 diabetes, as well as in obese non-
diabetic subjects [68]. It is demonstrated that PPARγ expres-
sion is not changed in old rats. The administration of rosigli-
tazone restores practically all changes in lipid and glucose
metabolism introduced by old age [69]. More importantly,
according to results of Diabetes Reduction Assessment with
Ramipril and Rosiglitazone Medication (DREAM) study,
rosiglitazonesubstantiallyreducesincidentoftype2diabetes
andincreasesthelikelihoodofregressiontonormoglycaemia
inadultswithimpairedfastingglucose,impairedglucosetol-
erance, or both [70].
Dramaticchangesinfatdepotsize,fattissuedistribution,
and function occur throughout life span [71]. Although total
body fat may decrease in old age, percent body fat declines
very little, and may even remain constant or increase. This
occurs because fat is redistributed from fat depots to other
sites. This decline in fat within traditional fat depots in oldAdnan Erol 5
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Figure 2: In aging organism, two important sites regarding the
energy metabolism, adipocyte with the increased lipogenesis, and
skeletal muscle with the decreased fat oxidation are shown. Possible
future therapeutic ﬁelds and expected beneﬁcial alterations are also
indicated.
age is accompanied by accumulation of fat in muscle, bone
marrow, and other sites outside fat depots. Reasonable ex-
planation for these signiﬁcant age-induced fat depot changes
came from the study showing that old animal preadipocytes
expressed less PPARγ. Hence, preadipocyte fatty acid han-
dling changes with aging, with increased susceptibility to
lipotoxicity and impaired fatty acid induced adipogenesis.
This,inturn,mayultimatelycontributetofattissuedysfunc-
tion, compromising capacity of fat tissue to protect other tis-
sues from lipid accumulation and lipotoxicity [72]. Conse-
quently, paradoxical lipotoxicty of fat cell progenitors poten-
tially reasons in systemic metabolic consequences.
Intriguingly, PPARγ +/− mice displayed greater insulin
sensitivity than their wild-type (WT) littermates did [73].
Further research, however, showed that this eﬀect occurred
only in aged animals. In other words, the PPARγ recep-
tor deﬁcient animals are relatively protected from the nor-
mal physiological age-induced decrease in insulin sensitivity
[74].Thustherapeuticmaneuversthatcouldproducerelative
PPARγ deﬁciency might be of clinical value for the treatment
of insulin resistance in old age [73].
Concerning the ageing process, PPARγ may perhaps be
thought of a “harmful” receptor, due to the combination of
itsroleinthethriftyresponseandtheincreasedcaloricintake
seen in modern “Western” diets [75]. At this point, PPARγ
can be divided agonists into two groups, classical full ago-
nists, which are represented by the TZDs, such as rosigli-
tazone and pioglitazone, and newer partial agonists, which
were developed, in large part, to reduce the side eﬀect of
weight gain observed with full agonists. Partial agonists are
compounds that produce activity below that of saturating
concentrations of a full agonist [50]. Partial agonism might
be an interesting approach to the therapy of type 2 diabetes,
particularly in elderly, because partial or minimal PPARγ ac-
tivation may have beneﬁcial eﬀects by stimulating insulin
sensitivity without promoting adipogenesis.
Reduction of PPARγ activity by small-molecule partial
antagonistsimprovesthemetabolicproﬁleinmice.Although
still at a preliminary stage, several compounds have been
identiﬁed that may prove eﬃcacious in the treatment of the
metabolic syndrome and type 2 diabetes [50, 75]. One of
these new generation compounds could prevent adipogen-
esis, insulin resistance, and obesity by blocking endogenous
ligand-induced activation of PPARγ. In addition, these com-
pounds may increase glucose disposal in peripheral tissues
(see Figure 2)[ 76].
Another concern of PPARγ activation by TZD use in the
e l d e r l yi sb o n ef r a c t u r e .P P A R γ activation by TZD may also
aﬀect bone through an increase in bone marrow adiposity
and a decrease in osteoblastogenesis, resulting in reduced
bone formation [77, 78]. Since PPARγ expression increases
in marrow mesenchimal cell with aging, PPARγ activation
by rosiglitazone resulted in distinctive changes in bone mi-
croarchitecture and strength [79]. Additionally, TZDs aﬀect
aromatase pathway, leading to decreased estrogen produc-
tion with an increase in bone resorption [80]. More impor-
tantly, DREAM [70] and ADOPT [81] trials clearly showed
the impact of TZDs on bone fracture risk in older women.
Old age is associated with dyslipidemia, obesity, and type
2 diabetes mellitus, which are the risk factors, increase the
majorcardiovasculareventsinlatelife[82].Thesealterations
in lipid metabolism arepartiallyrelatedtoaprofoundreduc-
tionintheliverexpressionandactivityofPPARα,andseveral
of its target genes, in old animals. Therefore, these animals
may become resistant to the hypotriglyceridemic eﬀectsof ﬁ-
brate class of hypolipidemic drugs, which are PPARα ligands
[83]. This may provide an explanation for the disappointing
primary outcome results of the large-scaled FIELD study, be-
cause the ages of the patients in this study signiﬁcantly were
in old-age group [84].
Fibrates and statins are the two most commonly used
hypolipidemic drugs. Statins mainly reduce intrahepato-
cyte cholesterol levels through the inhibition of hepatic
3-hydroxy 3-methylglutaryl-CoA reductase. Interestingly, it
was demonstrated that atorvastatin is a synthetic statin re-
versed the age-related reduction of hepatic PPARα.H o w -
ever, atorvastatin administration prevents the age-related
metabolic changes associated with the reduction in hepatic
PPARα expression and activity only in old male rats, senes-
cent females being practically unresponsive to the drug [85].
8. CALORIC RESTRICTION, LONGEVITY, AND PPARs
Increasing evidence demonstrates that CR profoundly aﬀects
the physiological and pathophysiological alterations associ-
ated with aging and markedly increases life span in several
species including mammals [35]. Recent studies on CR pro-
vide clear evidence that CR likely exerts its diverse beneﬁts
through its antioxidative ability to suppress age-related ox-
idative stress while upholding the antioxidant defense system
[9, 10].
CR is also known to alter expression of large number
of genes involved in lipid metabolism and insulin signaling.
Expression of many of the same genes is regulated by PPARs
actingastranscriptionfactors.Thissuggestsapossibilitythat6 PPAR Research
PPARs mediate the eﬀects of CR [35]. In a recent study, the
eﬀect of 2,4-thiazolidinedione, starting material of the var-
ious synthetic TZD, compared with the short-term CR on
the aging process. Study results showed that PPARγ acti-
vation suppresses age-induced inﬂammation and oxidative
stress via the down-regulation of NF-κB. It has been pro-
posed that the anti-inﬂammatory and antioxidative proper-
ties of PPARγ activators may be potential eﬀective therapeu-
tic approaches to the treatment and/or prevention of age-
induced inﬂammatory diseases (see Figure 1)[ 86].
Dwarf mice, which exhibit decreased levels of insulin, in-
sulin like growth factor (IGF)-I, and increased insulin sen-
sitivity, have defects in growth hormone action and share a
number of beneﬁcial phenotypic characteristics with rodents
onCRdiets.TheseshareddecreasesininsulinandIGF-Imay
bethebasisforbeneﬁcialphenotypiceﬀectsincommonwith
CR and dwarf mutations. Like CR animals, dwarf mice are
protected from spontaneous and chemically induced cancer,
age-dependent declines in immune function, and collagen
cross-linking ([87] and references therein). Gene array stud-
ies indicated that the genes regulated by PPARα were either
upregulated in dwarf mice or their expression increased in
response to PPARα agonist treatment, which was interpreted
as some of the beneﬁcial eﬀects associated with the dwarf
phenotype that may be caused by constitutive activation of
PPARα and regulated genes [88].
PPARα seems to play roles in long-term CR. The expres-
sion of the PPARα gene but not protein was increased in the
livers of CR animals [89]. PPARα-deﬁcient mice develop ox-
idative stress at an earlier age than aged-matched wild-type
mice. In addition to roles in lipid metabolism, PPARα likely
carries out other unexpected functions during CR. PPARα
was partially or completely required for CR to downregu-
late acute phase genes responsive to inﬂammatory cytokines,
possibly through the negative inﬂuence of PPARα on the im-
portantinﬂammatorygenes[87].PPARαactivatorsdiminish
tissue lipid peroxide levels, abrogate age-associated constitu-
tively active NF-κB, and reduce spontaneous cytokine pro-
duction in aged wild-type but not in PPARα-deﬁcient mice
[90]. PPARα agonist action on oxidative status might also
contribute to lower redox activation of transcription factors,
such as NF-κB and AP-1 [86].
Corton and Brown-Borg found signiﬁcant overlaps be-
tween the CR transcript proﬁles in wild-type mice and the
proﬁles altered by agonists of PPARα and hypothesized that
some eﬀects of CR are mediated by PPARα [87]. However,
activation of PPARα also regulates the genes in gluconeo-
genesis in addition to its well-known eﬀects on the genes
of fatty acid oxidation [87]. Therefore, impaired glucose ex-
cursion via PPARα agonist administration in elderly people
who are not in calorie restricted diet increases the formation
of ROS and induces hyperinsulinemia, which enhances the
steady-state level of oxidative stress [34]. Masoro hypothe-
sizedthatthelifetimemaintenanceofreducedlevelsofblood
glucose and insulin without compromising glucose fuel use
partly contributes to the antiaging actions of CR [91]. Thus
the identiﬁcation of higher aﬃnity and selective PPARα lig-
ands particularly for skeletal muscle and adipose tissue not
for liver, and the administration in the early periods might
slow aging and prevent age-associated metabolic disorders
(see Figure 2)[ 92].
A central question is whether the beneﬁts of CR are a
passive result of lower caloric intake or the consequence of
an active regulatory program. Molecular and genetic stud-
ies in model organisms have suggested that CR may be a
regulated process, with the silent information regulator 2
(SIR2)geneplayinganimportantrole.Mammalianortholog
of this gene, SIRT1, mediates a broad array of physiologi-
cal eﬀects that occur in animals on a CR diet [93]. SIRT1 is
widely distributed in mammalian tissues and partners with
diﬀerent eﬀectors [87]. One of them is PPARγ, which is re-
pressed by SIRT1 activation. SIRT1 activity is predicted to
counter PPARγ-mediated adipogenesis [94]. Given the im-
pact of SIRT1 on PPARγ activity and because PPARγ activ-
ity helps determine age-related insulin resistance [95], SIRT1
may have an important role in metabolic diseases and link
the eﬀects of food consumption to body fat mass and dis-
eases of aging [95]. Until now there is no experimental evi-
dence that SIRT1 represents the molecular link between re-
duced adiposity and increased lifespan. Considering the in-
sulin sensitizing eﬀects of PPARγ agonists, it is at least con-
troversial whether inhibition of PPARγ would be beneﬁcial
to human longevity [96]; but, it may remain an experimental
support for the above-mentioned harmful eﬀects of PPARγ
agonists. It is also interesting to speculate that the increased
frequency of atherosclerosis in old-age people could be a
PPARγ-driven maladapted macrophage response that occurs
when the stimulation of the innate immune response and
cholesterol eﬄux are overwhelmed by the proatherogenic ef-
fects [50, 75].
9. CONCLUSIONS
Aging is a complex stochastic process determined by genetic
and environmental factors. Similarly, the activity and func-
tions of PPARs in aging are highly confusing.
(1) Moderate levels of PPARγ activation are beneﬁcial be-
cause eﬃcient energy conservation and storage have
allowed survival through periods of food shortages.
However, aﬄuent lifestyles of elderly population in
industrialized world already exposed them to natu-
ral PPARγ ligands throwing this tightly regulated sys-
tem into a metabolic turmoil, so-called metabolic syn-
drome.
(2) PPARγ signaling plays an important role in the patho-
physiology of human age-related osteoporosis by in-
creasing the number of adipocytes in bone marrow
and decreasing the number of osteoblasts. Recent
DREAM study clearly indicated this adverse aﬀect of
the PPARγ agonist, rosiglitazone. Similarly, chronic
administration of TZDs was accompanied by fat ac-
cumulation in the bone marrow cavity and impaired
hematopoiesis, resulting in anemia [97].
(3) Collectively, modulating or clearly inhibiting PPARγ
activity in elderly, rather than activating it, might be
the preferred therapeutic strategy as an antiaging ap-
proach (see Figure 2) and also to treat age-associatedAdnan Erol 7
metabolic disorders including obesity, type 2 diabetes
and cardiovascular diseases.
(4) Recent data link adipose tissue, nutrition, and xenep-
hormesis as pivotally involved in the processes of ag-
ing and longevity [98, 99]. Resveratrol, a polypheno-
lic compound present in red grape and wine, stimu-
lates SIRT1 expression that extends life expectancy in
treatedanimalsviaCRmimeticactivity[95,99].Upon
food withdrawal Sirt1 protein represses and binds to
genes controlled by the fat regulator PPARγ (96).
(5) Age-induced decrease in PPARα expression may re-
vealtissuesunprotectedagainstacuteorchronicstress.
Therefore,itshouldbeaimedpharmacologicallytoin-
crease the aging-induced decrease of protein expres-
sion of PPARα because PPARα may play roles in stress
resistance and/or longevity. Currently, unique proven
strategy, which improves age-induced downregulation
in PPARα molecular system, is an exercise training
[100]. Once again, this ﬁnding underlines the impor-
tance of lifestyle modiﬁcation in aged people. The
administration of current pharmacological ligands of
PPARα such as ﬁbrates to geriatric patients may not
work expectedly because of the deﬁciency of their re-
ceptors.
(6) There is no change in the expression of PPARβ/δ
in aging cells. Physical exercise simulating actions of
PPARβ/δ on skeletal muscle seems to be PPARβ/δ ag-
onists that might be expected agents for the metabolic
disorders, particularly, of the age- associated (see
Figure 2). The outcome of ongoing clinical trails for
the therapeutic usefulness of these agents will provide
eagerly awaited results in the very near future.
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